OBJECTIVES: To evaluate selected Healthcare Effectiveness Data and Information Set (HEDIS) comprehensive diabetes care measures in the i3 Innovus database by using the Retrospective Analysis for Diabetes Action and Reporting (RADAR) tool. METHODS: i3 Innovus data assets including medical and pharmacy claims from May 2006 to May 2008 were used in the RADAR tool to assess the yearly rate of glycosylated hemoglobin (HbA1c) testing and low-density lipoprotein-cholesterol (LDL-C) screening. Other HEDIS comprehensive diabetes care–related measures reported by the RADAR tool included the rate of patients with (a) hypertension; (b) nephropathy; and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical utilization patterns along with medication adherence were also reported.  RESULTS: A total of 287,195 patients with diabetes were identified, with 92% of the patients identified as having type 2 diabetes. Mean age of the patients was 53 years, and 52% were male. Over 70% of the patients with diabetes had cardiovascular risk factors such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropathy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes patients received HbA1c testing, while 71% of the patients received LDL-C screening within one year. Testing within one year was less than the national HEDIS Medicaid 25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes care measures in the i3 Innovus database.  CONCLUSIONS: In this population, LDL-C screenings within one year for diabetes patients were above the national HEDIS low-performance level, while HbA1c testing within one year for diabetes patients was below the low-performance level, utilizing the RADAR tool for analyses. These findings indicate an opportunity for improvement.